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Hereditary hypophosphatemic rickets with hypercalciuria (HHRH) is a rare disorder of autosomal recessive in-
heritance that was ﬁrst described in a large consanguineous Bedouin kindred. HHRH is characterized by the presence
of hypophosphatemia secondary to renal phosphate wasting, radiographic and/or histological evidence of rickets,
limb deformities, muscle weakness, and bone pain. HHRH is distinct from other forms of hypophosphatemic rickets
in that affected individuals present with hypercalciuria due to increased serum 1,25-dihydroxyvitamin D levels and
increased intestinal calcium absorption. We performed a genomewide linkage scan combined with homozygosity
mapping, using genomic DNA from a large consanguineous Bedouin kindred that included 10 patients who received
the diagnosis of HHRH. The disease mapped to a 1.6-Mbp region on chromosome 9q34, which contains SLC34A3,
the gene encoding the renal sodium-phosphate cotransporter NaPi-IIc. Nucleotide sequence analysis revealed a
homozygous single-nucleotide deletion (c.228delC) in this candidate gene in all individuals affected by HHRH.
This mutation is predicted to truncate the NaPi-IIc protein in the ﬁrst membrane-spanning domain and thus likely
results in a complete loss of function of this protein in individuals homozygous for c.228delC. In addition, compound
heterozygous missense and deletion mutations were found in three additional unrelated HHRH kindreds, which
supports the conclusion that this disease is caused by SLC34A3 mutations affecting both alleles. Individuals of the
investigated kindreds who were heterozygous for a SLC34A3 mutation frequently showed hypercalciuria, often in
association with mild hypophosphatemia and/or elevations in 1,25-dihydroxyvitamin D levels. We conclude that
NaPi-IIc has a key role in the regulation of phosphate homeostasis.
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Hereditary hypophosphatemic rickets with hypercalci-
uria (HHRH [MIM 241530]) is a rare disorder of au-
tosomal recessive inheritance that was ﬁrst described in
a large consanguineous Bedouin kindred (Tieder et al.
1985). This disorder is characterized by the presence of
hypophosphatemia secondary to renal phosphate wast-
ing, radiographic and/or histological evidence of rickets,
limb deformities, and bone pain (Tieder et al. 1985,
1987; Gazit et al. 1991). Hypophosphatemia in patients
with HHRH leads to appropriate stimulation of renal
1a-hydroxylase causing increased synthesis and serum
levels of the biologically active vitamin D metabolite
1,25-dihydroxyvitamin D (1,25(OH)2D). As a result, in-
testinal absorption of calcium is enhanced, resulting in
increased urinary calcium excretion (Tieder et al. 1985).
Increased serum 1,25(OH)2D levels and hypercalciuria
distinguish HHRH from other hypophosphatemic dis-
orders, such as X-linked hypophosphatemia (XLH
[MIM 307800]), which is caused by mutations in PHEX
(phosphate-regulating gene with homology to endopep-
tidases on the X chromosome [HYP Consortium 1995;
Holm et al. 1997]) and autosomal dominant hypo-
phosphatemic rickets (ADHR [MIM 193100]), which
is caused by mutations in the gene encoding ﬁbroblast
growth factor 23 (FGF23) (ADHR Consortium 2000).
The kidney is a major regulator of phosphate homeo-
stasis. Three classes of sodium-phosphate cotransporters
are expressed in the kidney. The type I cotransporter,
NaPi-I (SLC17A1), and the type II cotransporters NaPi-
IIa (SLC34A1) and NaPi-IIc (SLC34A3) are expressed
predominantly at the renal brush border membrane of
the proximal tubules, where the bulk of ﬁltered phos-
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phate is reabsorbed (Segawa et al. 2002; Murer et al.
2000, 2004). The type III transporters, Glvr-1 (SLC20A1)
and Ram-1 (SLC20A2), are two ubiquitously expressed
retroviral receptors that account for !1% of the mRNAs
encoding the different renal sodium-phosphate cotrans-
porters (Tenenhouse et al. 1998) and likely serve as
“housekeeping” transporters (Kavanaugh and Kabat
1996). The type II cotransporter NaPi-IIb (SLC34A2) is
not expressed in the kidney but is present in several other
tissues, particularly the small intestine, where it is in-
volved in the absorption of dietary phosphate (Hilﬁker
et al. 1998).
Both NaPi-IIa and NaPi-IIc, as well as their respective
murine orthologs Npt2a and Npt2c, are regulated in a
similar fashion by parathyroid hormone (PTH), FGF23,
and dietary phosphate. PTH decreases the abundance
of Npt2a protein in the renal brush border membrane
(Kempson et al. 1995), and preliminary data have shown
that Npt2c is equivalently regulated by this hormone
(Miyamoto et al. 2002, 2004). Similarly, renal expres-
sion of both cotransporters is reduced by FGF23, a re-
cently identiﬁed important regulator of phosphate ho-
meostasis (Bai et al. 2004; Larsson et al. 2004; Shimada
et al. 2004a, 2004c). Furthermore, Hyp mice, which
have elevated levels of endogenous FGF23 (Liu et al.
2005), show reduced expression of both renal sodium-
dependent phosphate cotransporters (Tenenhouse et al.
2003), whereas mice lacking FGF23 show increased ex-
pression of Npt2a (Shimada et al. 2004b; Sitara et al.
2004) consistent with the renal phosphate retention seen
in these animals. Lastly, phosphate deprivation increases
Npt2a and Npt2c expression in the proximal tubule
(Ohkido et al. 2003; Madjdpour et al. 2004). Thus, both
renal sodium-dependent phosphate cotransporters are
important targets for hormonal and dietary regulation
of renal tubular phosphate reabsorption.
Homozygous ablation of the murine gene encoding
Npt2a (Slc34a1) leads to hypophosphatemia, renal phos-
phate-wasting, increased serum 1,25(OH)2D levels, and
hypercalciuria (Beck et al. 1998). These ﬁndings are evi-
dent at weaning, but the magnitude of these changes
decreases with increasing age. Furthermore, Npt2a-
ablated mice lack the typical features of rickets (Beck et
al. 1998; Gupta et al. 2001; Tenenhouse 2005). It was,
therefore, not too surprising that SLC34A1 mutations
were excluded in genomic DNA from affected members
of several kindreds with HHRH, including the original
Bedouin kindred (Jones et al. 2001; van den Heuvel et
al. 2001). Mutations in SLC17A1, another plausible
candidate gene that is located in chromosome region
6p23-p21.3, were also excluded in patients with HHRH
(Kos 1998). To identify the genetic defect responsible for
HHRH, we performed a genomewide search for linkage
combined with homozygosity mapping with the use of
genomic DNA from a consanguineous Bedouin kindred
described elsewhere (Tieder et al. 1985, 1987). A ho-
mozygous deletion in SLC34A3, c.228delC, was found
in all affected individuals and is predicted to result in a
complete loss of function of the encoded sodium-depen-
dent cotransporter NaPi-IIc. Different mutations in the
same gene were also found in affected members of three
small and unrelated kindreds with HHRH that were
described elsewhere (Jones et al. 2001; Sermet-Gaudelus
et al. 2001).
Methods
Human Subjects
For the present study, we used genomic DNA samples from
the previously described Bedouin kindred (ﬁg. 1A) and kin-
dreds A, C, and D (ﬁg. 2) (Tieder et al. 1985, 1987; Jones et
al. 2001; Sermet-Gaudelus et al. 2001). For consistency, all
codes identifying individuals are the same as those used by
Jones et al. (2001). The studies have been approved by insti-
tutional review committees, and informed consent has been
obtained for all participants.
Search for the Genetic Locus of HHRH
A genomewide scan was performed on samples from 63
individuals from the Bedouin kindred, including 10 individuals
with HHRH. A set of 389 microsatellite markers, described
by Mira et al. (2003), with an average intermarker distance
of 9.1 cM was used. To follow up suggestive regions of linkage
from the genomewide scan, 13 additional markers from chro-
mosomes 1 and 9 were selected from the deCODE Genetics
(Kong et al. 2002) or the Marshﬁeld (Marshﬁeld Center for
Medical Genetics Web site) genetic maps. Genotyping was per-
formed at the McGill University and Genome Quebec Inno-
vation Centre, as described elsewhere (Mira et al. 2003).
To further deﬁne the candidate region on chromosome 9,
seven new markers were developed on the basis of the May
2004 freeze of the UCSCGenome Browser database (Karolchik
et al. 2003), as described elsewhere (Bastepe et al. 1999; Bas-
tepe and Ju¨ppner 2000). These markers were genotyped by
PCR ampliﬁcation of 50 ng of DNA in 96-well plates (Corning)
in a ﬁnal volume of 10 ml/well by use of 32P-labeled forward
oligonucleotide primers and the Qiagen PCR kit (see table 1
for primer sequences and thermal cycler conditions). After the
addition of 10 ml of 2# loading dye, 5 ml of each PCR product
were separated on a 5% Long Ranger (Cambrex)/7 M urea
gel, as described elsewhere (Bastepe et al. 2001). After the gel
was dried and exposed to Kodak MR ﬁlm for 3–18 h, the
ﬁlms were developed and the alleles were scored.
Nucleotide Sequence Analysis
SLC34A3 spans ∼5 kb of genomic DNA. The entire
SLC34A3 gene was ampliﬁed by PCR (Qiagen PCR kit) in
four overlapping fragments by use of primer pairs 17 and 18,
19 and 20, 21 and 22, and 23 and 24 (see table A1 for primers
and thermal cycler conditions). The PCR products were pu-
riﬁed using spin columns (Qiagen), and nucleotide sequence
analysis was performed using 20 ng/100 bp DNA and nested
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Figure 1 Genealogical, clinical, and genetic ﬁndings in a previously published Bedouin kindred with HHRH. A, Partial pedigree of the
Bedouin kindred. Blackened circles or squares indicate individuals who developed rickets during childhood, along with renal phosphate wasting,
hypophosphatemia, and hypercalciuria. Unblackened symbols without a question mark (?) indicate individuals who were healthy; the question
mark indicates unknown phenotype. A symbol with only the right upper quadrant blackened indicates an individual affected with only hyper-
calciuria. Samples for individuals with symbols with dashed outlines on the gray background were unavailable for genotyping. B, Haplotypes
for chromosome region 9q34 between markers D9S1826 and D9S1838. Alleles for microsatellite markers are designated in bp or are coded;
for the c.228delC mutation, “” and “” indicate the presence and absence of the deletion, respectively. The haplotype associated with HHRH
is depicted by numbers on a gray background; regions that were excluded because of inferred ancestral recombination events are shown by
numbers on a white background that are delineated with a horizontal black line. C, Endonuclease digestion to identify the c.228delC mutation.
The deletion abolishes an StuI site. Therefore, PCR-ampliﬁed DNA from the mutant allele (451 bp) could not be digested with this endonuclease.
In contrast, DNA ampliﬁed from the wild-type allele yielded 359- and 92-bp fragments (see also table 2).
forward or reverse primers (100 ng each) at the Massachusetts
General Hospital DNA Sequencing Core Facility.
SNP Analysis in Controls
DNA samples were obtained from the Harvard Partners
Center for Genetics and Genomics (Cambridge, MA) (84%
white, 8% black, 5% Asian, and 3% Hispanic) ( ). Bed-np 95
ouin, Turkish, and Australian Aboriginal controls were not
available to us; thus, we did not have the most-appropriate
controls for all kindreds. When possible, sequence variations
were analyzed in these control samples by restriction endo-
nuclease digestion and subsequent 2% agarose/TAE gel elec-
trophoresis, by use of appropriate PCR primers that amplify
across the SNP. The region encompassing the 101-bp deletion
(g.2259_2359del) was ampliﬁed with primers 21 and 22, fol-
lowed by nested PCR with primers 173 and 174 to generate
a wild-type 480-bp product and a mutant 380-bp product (see
tables 2 and A1 for primers and thermal cycler conditions).
Multiplex PCR assays for the analysis of c.586GrA
(p.G196R) and c.575CrT (p.S192L) were designed and per-
formed at the Harvard Partners Center for Genetics and Gen-
omics by use of Sequenom SpectroDESIGNER software and
sequence containing the SNP and 100 bp on each side of the
SNP (Lazarus et al. 2002). Single-primer extension across the
SNP was performed as described elsewhere (Lazarus et al.
2002), and extension products were then spotted onto a 384-
well spectroCHIP before being ﬂown in the matrix-assisted
laser desorption/ionization–time of ﬂight (MALDI-TOF) mass
spectrometer for analysis (see table A2 for primer information
and experimental details).
Statistical Analysis
Since the mode of inheritance of HHRH was not deﬁnitively
established, we used the maximized maximum likelihood score
(MMLS) screening method of Greenberg et al. (1998) for anal-
ysis of the genomewide scan data and 13 additional markers
on chromosome 9. In brief, two models were analyzed: a re-
cessive model with 50% penetrance and a dominant model
with 50% penetrance. The MMLS is the maximum LOD score
obtained using one of the two models. Singlepoint parametric
LOD scores at different recombination fractions were calcu-
lated using a pedigree of 294 individuals from the Bedouin
kindred that connected all 10 patients with HHRH and con-
tained 14 inbreeding/marriage loops. Linkage analyses were
182 The American Journal of Human Genetics Volume 78 February 2006 www.ajhg.org
Figure 2 Genetic ﬁndings in three previously published kindreds with HHRH (A, C, and D). In the pedigrees, the use of symbols and
shading is the same as in ﬁgure 1 unless otherwise indicated. Haplotypes associated with HHRH are depicted by numbers on a dark-gray or
light-gray background. Mutations were identiﬁed by nucleotide sequence analysis and were conﬁrmed by restriction endonuclease digestion of
the appropriate PCR products when possible (see table 2). Note that, in kindred D, c.1579_1581del cannot be unambiguously phased.
performed using the MLINK-like option of Superlink version
1.4 (Fishelson and Geiger 2002). Marker allele frequencies
were estimated by counting all genotyped individuals. The dis-
ease-allele frequency was arbitrarily set at 0.1 for the recessive
model and at 0.01 for the dominant model (Pal et al. 2001),
since no estimates of the disease prevalence were available. To
adjust for multiple testing with these two models, the LOD
scores should be compared with signiﬁcance thresholds that
are 0.3 LOD units higher than the standard ones.
Results
Clinical Information
The Bedouin kindred, a subset of which is shown in
ﬁgure 1A, has been well characterized elsewhere (Tieder
et al. 1985, 1987; Gazit et al. 1991).
The parents of the affected child in kindred A (of
Turkish origin) were initially reported to be second cous-
ins (Jones et al. 2001; Sermet-Gaudelus et al. 2001);
however, additional genealogic information did not con-
ﬁrm this. The affected female (V-1) was ﬁrst evaluated
at age 7 years and 7 mo because of genua vara—which
ultimately required surgical correction—growth delay,
and radiographical signs of rickets, but she had no frac-
tures. At the time of presentation, the patient had ne-
phrocalcinosis, as determined by renal ultrasound, in the
absence of glycosuria, proteinuria, and acidosis; her re-
maining serum and urinary chemistries revealed hypo-
phosphatemia due to renal phosphate wasting, hyper-
calciuria, and elevated 1,25(OH)2D levels (table 3). Bone
mineral density (BMD) evaluated at age 13 years was
reduced (total hip z score 3.8; lumbar spine z score
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Table 1
New Microsatellite Markers Used for Linkage Analysis
MARKER REPEAT
PRIMER SEQUENCE
(5′r3′)
POSITION ON
CHROMOSOME 9aForward Reverse
CB-3 GT CGAAACTCAACAAGCAGCAG ACACATGCACACAACACG 136085575
CB-4 GACAG TTGCACCACTGTACCTGTA CGTTGGGGGGAAGTATTTG 136179906
CB-9 AAAT GGGCAACAAGAGTGAAACTAC GTGGTTGTTAGGAGTCTGGA 137208898
CB-11 AAT CCAGGAGGTGGAGATTGGA CCTACCACCCTAGCCAACAA 137771033
CB-14 ATAGA GGTGACAGAGCAAGACTTGACTAA GTTTGAACCCAGGAATTGGA 136257774
CB-18 AC GTCACCCCAACCTCAAGCTA TCCATACTCACCCCCATACAA 136214185
CB-26 CAAA ATTAGTCGGATGTGGTGACG CAAATTAGGCCCCATTCTCA 135762525
NOTE.—For PCR in a ﬁnal volume of 50 ml, the thermal cycler conditions (Mastercycler gradient) after an initial de-
naturation at 94C for 5 min were 40 cycles at 94C for 50 s, 58C for 50 s, and 72C for 50 s, with a ﬁnal extension at
72C for 10 min.
a Physical map position on chromosome 9, UCSC Genome Browser, May 2004 release.
2.4). Since the initial reports describing family A (Jones
et al. 2001; Sermet-Gaudelus et al. 2001), two additional
younger siblings of V-1 have been evaluated: V-2 had
normal serum and urine chemistries, and V-3 also had
normal serum chemistry but had an increased calcium-
to-creatinine ratio of 1.44 mmol/mmol (upper limit of
normal for children younger than 2 years old is 1.0
mmol/mmol) and slightly reduced tubular reabsorption
of phosphate (TRP) (see table 3). Their father (IV-4) and
mother (IV-3) had, when ﬁrst evaluated, hypophospha-
temia and elevated 1,25(OH)2D levels in the setting of
vitamin D deﬁciency, which did not persist after vitamin
D repletion. However, the mean urinary calcium-to-
creatinine ratio remained above the normal range
throughout the observation period of 3 years for both
parents (0.23–0.74 mmol/mmol; upper limit of normal
for adults 0.4). Intact PTH was in the low- to mid-
normal range for all individuals of kindred A (data not
shown).
In kindred C, the affected individual II-2 presented at
age 14 years with gradual onset of bilateral knee and
ankle pain. At age 13 years, he passed a calcium oxalate
kidney stone. There were bilateral genua valga on initial
examination, and he walked with a limp. He was found
to have hypophosphatemia, an elevated urinary calcium-
to-creatinine ratio, and an increased 1,25(OH)2D level
(see table 3), whereas the concentration of 25-hydroxy-
vitamin D and midmolecule PTH were within normal
limits (data not shown). His bone turnover was accel-
erated, as indicated by an increased urinary excretion of
N-telopeptide (805 nmol bovine collagen equivalents/
mmol creatinine; normal !86) and pyridinoline (451
nmol/mmol creatinine; normal 17–410), a urinary de-
oxypyridinoline excretion at the upper end of normal
(115 nmol/mmol creatinine; normal 2–118), and an in-
creased serum alkaline phosphatase (910 U/liter; normal
!350). There was no evidence of hyperoxaluria, pro-
teinuria, or acidosis. Radiographic studies were remark-
able for osteopenia, an osteochondroma emanating from
the left ﬁbula, and subtle rachitic changes—that is, mild
fraying of the metaphyses and epiphyses. The patient’s
BMD was reduced to 0.367 g/cm2 at the hip (z score
4.7; t score 4.41) and to 0.447 g/cm2 at the lumbar
spine (z score3.7; t score5.26). With oral phosphate
supplements, his lumbar spine BMD improved to 0.977
g/cm2 (z score –1.0; t score 1.0) by age 20 years. A
renal ultrasound at age 21 years showed no abnormal-
ities. His mother (I-2) is of Irish, French, and German
descent and had normal biochemistry, with the exception
of slightly elevated 1,25(OH)2D levels and an increased
urinary calcium-to-creatinine ratio. His father (I-1) is of
Scottish descent and had hypophosphatemia and ele-
vated 1,25(OH)2D levels but normal urinary calcium
excretion (see table 3). There was no history of consan-
guinity in kindred C.
In kindred D, which is of mixed white and Aboriginal
origin from Australia, three individuals are affected by
HHRH (II-3, II-4, and II-5). II-5, the index patient in
the report by Jones et al. (2001), had severe rickets with
bowing, which required stapling of the lower femoral
epiphyses. Her bone histology showed severe osteo-
malacia with increased cellularity. The sisters (II-3 and
II-4) had milder bone disease. All three siblings met bio-
chemical criteria for HHRH, including hypophospha-
temia, hypercalciuria, and elevated 1,25(OH)2D levels
(see table 3). Thus, the diagnoses for these individuals
have changed since the initial publication (Jones et al.
2001). Lumbar BMD was 0.846 g/cm2 for II-4 (z score
3.0) and 0.617 g/cm2 for II-5 (z score 1.0). Their
father (I-2) had abnormal bone histology, with increased
osteoid surfaces and increased rate of bone formation.
He had hypercalciuria and hypophosphatemia but nor-
mal 1,25(OH)2D levels. Their mother (I-3) also had ab-
normal bone histology, with an increased rate of bone
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Table 2
Ampliﬁcation and Restriction Endonuclease Digestion to Conﬁrm Mutations/SNPs
MUTATION/SNP EXON PRIMERS
AMPLICON
SIZE
(bp) ENZYME
NO. OF
CONTROL
DNAS
DIGESTION FRAGMENTSa
(bp)
Genotype 11 Genotype 12 Genotype 22
c.1402CrT (p.R468W) 13 52 and 53 336 BtsI 95 CC (95): 283, 53 CT (0): 336, 283, 53 TT (0): 336
c.1579_1581del (p.L527del) 13 52 and 53 336 BseRI 86 Wt (86): 223, 113 Het (0): 336, 223, 113 Mut (0): 336
c.228delC 4 32 and 33 451 StuI 94 Wt (94): 359, 92 Het (0): 451, 359, 92 Mut (0): 451
c.413CrT (p.S138F) 5 32 and 33 451 BmgBI 95 CC (95): 352, 99 CT (0): 451, 352, 99 TT (0): 451
c.1538TrA (p.V513E) 13 52 and 53 336 AluI 48 TT (29): 196, 140 TA (19): 336, 196, 140 AA (0): 336
NOTE.—The region of SLC34A3 ﬂanking the mutation/SNP was ampliﬁed by PCR in a ﬁnal volume of 20 ml by use of the indicated primers
(table A1) (Qiagen PCR kit); the thermal cycler conditions after an initial denaturation at 94C for 5 min were 35 cycles at 94C for 1 min,
60C or 65C for 1 min, and 72C for 3 min, followed by a ﬁnal extension at 72C for 10 min. PCR products were then subjected to restriction
endonuclease digestion to obtain the indicated genotype-speciﬁc fragments on 2% agarose/TAE gel electrophoresis.
a Genotypes are followed by the respective fragment(s), given in bp, and the number of controls with a particular genotype is in parentheses.
Het p heterozygote; Mut p mutant; Wt p wild type.
formation, but normal osteoid surfaces. She had mild
genua valga and hypercalciuria but normal serum phos-
phate and 1,25(OH)2D levels. One half-brother (II-1)
died from causes unrelated to bone disease. The half-
sister (II-2) had hypercalciuria but no other abnormal-
ities. II-6 was phenotypically normal. There is no report
of kidney stones in kindred D, nor were abnormalities
seen on renal ultrasonography for II-3, II-4, or II-5.
There was no known consanguinity in kindred D.
Genetic Analysis
An MMLS screening model was used to analyze the
genomewide scan data on 63 individuals in the Bedouin
kindred who were connected in a pedigree of 294 in-
dividuals with 14 inbreeding/marriage loops. The high-
est LOD score of 3.34 was obtained at markerD9S1838
by use of the recessive model (table 4). D9S1838 was
the most telomeric marker on chromosome 9q in the
initial screen. Additional markers that ﬂank D9S1838
were identiﬁed (D9S158, D9S905, and D9S2168), but
these markers did not change the evidence for or against
linkage and could not narrow the candidate region.
However, examination of the genotypes for the 10 pa-
tients with documented HHRH showed that all patients,
with the exception of V-89 and VI-75, were homozygous
for D9S1838 (ﬁg. 1B). At marker D9S1826, V-89 and
VI-75 were homozygous, but V-29, VI-64, and V-83
were heterozygous. Thus, under the assumption that
there existed one disease-causing mutation in a homo-
zygous chromosomal segment inherited identically by
descent, the HHRH locus was predicted to be between
D9S1826 and D9S1838.
To reﬁne the boundaries of this locus, publicly avail-
able sequence databases were searched to identify seven
newmicrosatellite markers, whichwere used to genotype
a subset of DNA samples (ﬁg. 1B and table 1). For
marker CB-9, all 10 patients were homozygous for the
same allele, whereas all genotyped parents and grand-
parents were heterozygous. Patient V-83 was heterozy-
gous for three markers (CB-3, CB-4, and CB-18) cen-
tromeric to CB-9, and patients V-89 and VI-75 were
heterozygous for a marker (CB-26) telomeric to CB-9.
Thus, under the assumption that heterozygosity repre-
sents ancestral recombinants, the candidate interval
could be reduced to a 1.6-Mbp region between CB-18
and CB-26. The March 2004 release of the human ge-
nome sequence from the National Center for Biotech-
nology Information (NCBI) revealed 70 known or pre-
dicted genes in the linked interval, including a likely
candidate gene, SLC34A3. This gene encodes the renal
sodium-dependent phosphate cotransporter NaPi-IIc,
which is involved in renal phosphate handling (Segawa
et al. 2002) and spans ∼5 kb on contig NT_024000.16,
comprising 13 exons, which give rise to a 2.1-kbmRNA.
The entire SLC34A3 gene was PCR-ampliﬁed in four
overlapping fragments to search for mutations in the
DNA from patient VI-75 (see table A1); these fragments
were submitted for sequence analysis. A homozygous
single-nucleotide deletion was identiﬁed that affects cy-
tosine at position 228 of the cDNA sequence (c.228delC;
numbering is according to cDNA [GenBank accession
number NM_080877.1] and starts at the initiator
ATG). In addition, three homozygous nucleotide changes
were identiﬁed in patient VI-75. Two of these SNPs,
c.558GrA and c.757TrC, are silent substitutions at co-
dons Q186 and L253, respectively, whereas the third
represents a nonsynonymous common polymorphism,
c.1538TrA (p.V513E) (tables 2 and 5; the SNPs pre-
sented in table 5 were submitted to the NCBI dbSNP
database.)
The c.228delC deletion causes a shift in the ORF after
codon 76, which is predicted to result in the translation
of a novel sequence of 74 aa that is unrelated to NaPi-
IIc and is then followed by a termination codon at co-
don 151. The predicted protein thus lacks all eight
membrane-spanning domains as well as the C-terminal
www.ajhg.org Bergwitz et al.: NaPi-IIc Mutations Cause HHRH 185
Table 3
Clinical Data for Kindreds A, C, and D
Kindred
and Individual
Age at
Measurement
(years)
Serum
Phosphatea
(mmol/liter)
TRPb
(%)
Urine
Calcium/Creatininea
(mmol/mmol)
Serum
1,25(OH)2D
a
Kindred A:
IV-3 32–35 .72–1.04 (.85–1.20) 91–96 .23–.64 (!.4) 46–140 (15–60) pg/ml
IV-4 31–34 .68–.94 (.85–1.20) 81–88 .38–.74 (!.4) 22–66 (15–60) pg/ml
V-1 8–13 .71–.86 (1.20–1.70) 70–75 .95–1.4 (!.4) 73–103 (30–70) pg/ml
V-2 6 1.35 (1.20–1.70) 91 .33 (!.4) 40 (30–70) pg/ml
V-3 1.6 1.85 (1.50–1.80) 80 1.44 (!1.0) 38 (30–120) pg/ml
Kindred C:
I-1 48 .42 (.81–1.45) 78 .14 (!.4) 72 (20–65) pg/ml
I-2 45 1.03 (.81–1.45) 88 .51 (!.4) 68 (20–65) pg/ml
II-1 15 1.00 (.97–1.61) 93 .11 (!.4) ND
II-2 14 .77 (.97–1.61) 82 .64 (!.4) 97 (20–65) pg/ml
Kindred D:
I-2 48 .74–.89 (.79–1.37) ND .50 (!.4) 96 (38–162) pmol/liter
I-3 36 .97 (.79–1.37) ND 1.00 (!.4) 79 (38–162) pmol/liter
II-1 19 .90 (.79–1.37) ND .66 (!.4) 68 (38–162) pmol/liter
II-2 17 .80 (.79–1.37) ND .61 (!.4) 94 (38–162) pmol/liter
II-3 14 .75–.93 (.95–1.85) 80 .57 (!.4) 240 (38–162) pmol/liter
II-4 11 .75–.91 (.95–1.85) 89 1.03 (!.4) 344 (38–162) pmol/liter
II-5 9 .77–1.13 (.95–1.85) 87 .79 (!.4) 1566 (38–162) pmol/liter
II-6 16 .96 (.79–1.37) ND .24 (!.4) 68 (38–162) pmol/liter
NOTE.—The IDs of individuals with compound heterozygous SLC34A3 mutations are indicated in bold italics.
ND p not determined.
a Given in parentheses are age-dependent normal values.
b Calculated as 100 # [1  (urine phosphate # serum creatinine)/serum phosphate # urine creatinine)]; normal
range is 85%–95%.
intracellular tail of NaPi-IIc, predicting a complete loss
of function of this sodium-dependent phosphate cotrans-
porter (ﬁg. 3). The c.228delC mutation removes a rec-
ognition site for the endonuclease StuI, making it pos-
sible to readily assay the presence or absence of the
identiﬁed mutation (see table 2). Using this assay,
DNA from all 22 individuals was analyzed (ﬁg. 1C).
All patients affected by HHRH were homozygous for
c.228delC, whereas all available parents and grandpar-
ents were heterozygous for this deletion. The c.228delC
deletion was not found in 188 alleles from 94 controls
(table 2).
We next searched for SLC34A3 mutations in three
unrelated, previously reported kindreds with at least
one member affected by HHRH (Jones et al. 2001;
Sermet-Gaudelus et al. 2001). As shown in ﬁgure 2,
compound heterozygous missense and frameshift mu-
tations were identiﬁed in the affected female V-1 of kin-
dred A. Missense mutation c.586GrA (p.G196R) was
paternally inherited, whereas the other missense muta-
tion, c.1402CrT (p.R468W), was maternally inherited.
These two nucleotide changes were absent in the unaf-
fected sibling and were not identiﬁed in 160 and 190
control alleles. The hypercalciuric brother (V-3) had in-
herited the maternal allele with the missense mutation
c.1402CrT (p.R468W). In kindred C, the affected male
(II-2) inherited one of the missense mutations identiﬁed
in kindred A, c.586GrA (p.G196R), whereas a 101-bp
deletion within intron 9, g.2259_2359del, was inherited
from his mother. Neither mutation was found in 160
control alleles. In kindred D, the female who had ﬁrst
received the diagnosis of HHRH (II-5) has one mater-
nally inherited mutation, c.413CrT (p.S138F), and one
paternally inherited mutation, c.575CrT (p.S192L).
Parental origin of a third mutation, c.1579_1581del
(p.L527del), could not be conﬁdently assigned. These
three mutations were not found in 190, 160, and 172
control chromosomes. The sisters II-3 and II-4, who
were classiﬁed as having HHRH on the basis of more-
recent ﬁndings, were genotypically identical to II-5 with
respect to the SLC34A3mutations and ﬂanking markers
(see ﬁg. 2 and table 3).
Discussion
Evidence That NaPi-IIc Mutations Cause HHRH
A genomewide linkage scan combined with a homo-
zygosity mapping approach in an extended Bedouin kin-
dred was used to map the genetic defect responsible for
HHRH to a 1.6-Mbp interval in chromosome region
9q34. SLC34A3, a plausible candidate gene in this re-
gion, was sequenced, and all individuals with HHRH
were found to be homozygous for a 1-nt deletion,
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Table 4
Maximal LOD Scores for Each Chromosome Derived from the
Genomewide Scan with Recessive and Dominant Disease Models
CHROMOSOME
AND POSITION (cM) MARKER
DOMINANT
MODEL
RECESSIVE
MODEL
LOD v LOD v
1:
179.98 D1S1625 .918 0 1.160 0
218.46 D1S1678 1.667 0 .513 .1
2:
47.97 D2S405 .127 .2 .218 .15
99.41 D2S1777 .708 0 .172 .2
3:
89.91 D3S4542 .986 0 1.702 0
4:
33.96 D4S3340 .412 .2 .655 0
60.16 D4S1627 .155 .2 .515 .2
5:
168.49 D5S1475 .840 0 .887 .1
6:
92.85 D6S1270 1.313 0 .040 .2
102.81 D6S1056 .063 0 1.480 0
7:
17.17 D7S2200 .901 0 .112 .2
103.63 D7S1813 .562 0 .273 .1
8:
26.43 D8S1106 .400 0 .484 .2
94.17 D8S1123 .159 .2 .005 .15
9:
163.84 D9S1838 1.834 0 3.341 0
10:
109.98 D10S1739 1.322 0 .538 .075
117.42 D10S677 1.489 0 .136 .15
11:
33.02 ATA34E08 .141 .2 .409 .2
123.00 D11S4464 .975 0 .267 .15
12:
56.38 D12S1663 1.150 0 .247 .15
13:
63.90 D13S317 .261 .2 .089 .2
14:
55.82 D14S587 .753 0 .059 .2
105.53 D14S617 .092 .2 .724 .025
15:
52.33 D15S643 .202 .1 .003 .2
60.17 D15S1507 .213 .1 .631 .1
16:
8.16 D16S2622 .225 .2 .692 .025
17:
.63 D17S1308 .172 .2 .097 .15
82.00 D17S1290 .013 .2 .010 .2
18:
96.48 D18S1270 .728 0 .773 .05
19:
68.08 D19S178 .417 .15 .329 .1
92.56 D19S418 .591 .05 .115 .2
20:
21.15 D20S115 .628 0 .115 .2
42.28 D20S471 .089 .2 .123 .2
21:
36.77 D21S1440 .419 0 .703 .075
22:
24.74 D22S1167 .503 .1 .047 .2
32.39 D22S685 .155 .2 .173 .2
X:
52.63 DXS1068 .379 .075 1.027 .001
165.11 DXS9908 .419 .1 .120 .2
NOTE.—See the “Methods” section for a detailed description of the
search for the genetic locus of HHRH. LOD scores are not corrected
for multiple testing.
c.228delC. This putative mutation is predicted to result
in a shift in the ORF after amino acid residue 76 and
to produce a presumably nonfunctional NaPi-IIc protein
that is truncated within the ﬁrst membrane-spanning do-
main (Segawa et al. 2002). Consistent with an important
role for NaPi-IIc in the pathogenesis of HHRH, several
compound heterozygous missensemutations or deletions
were found in affected individuals from three additional
unrelated kindreds but were not present in healthy con-
trols. In kindred D, three different SLC34A3 variations
were identiﬁed in the patients with HHRH. It remains
to be determined, however, whether the identiﬁed amino
acid changes contribute to the phenotype in each of these
patients, since ethnically matched controls were not al-
ways available to exclude the possibility that the nucle-
otide changes represent rare polymorphisms. We would,
however, conclude from the ﬁndings above that the mu-
tations affecting both SLC34A3 alleles, which presum-
ably lead to complete or partial loss of a functionalNaPi-
IIc protein, cause HHRH in our kindreds.
Physiological Role for NaPi-IIc Deﬁned by SLC34A3
Mutations in Patients with HHRH
SLC34A3 encodes NaPi-IIc, a type II electroneutral,
sodium-dependent phosphate transporter (Segawa et al.
2002), which shares signiﬁcant amino acid identity with
NaPi-IIa (54% between the two human cotransporters).
Both cotransporters are expressed predominantly in the
brush border membrane of proximal renal tubular cells
(Murer et al. 2004). NaPi-IIa was previously thought to
be the most important determinant of renal phosphate
handling and thus overall phosphate homeostasis. Con-
sistent with this conclusion, it was shown that the rel-
ative expression of Npt2a is an order of magnitude
higher than that of Npt2c in kidneys of wild-type mice
and rats maintained on a normal-phosphate diet (Se-
gawa et al. 2002; Ohkido et al. 2003). Furthermore, on
the basis of hybrid depletion experiments of rat kidney
poly-A RNA in Xenopus oocytes, Npt2c was thought
to be rate-limiting only during weaning and to contrib-
ute little to total sodium-dependent phosphate cotrans-
port in adult rats (Segawa et al. 2002). On the basis of
these data, NaPi-IIc was predicted to contribute 15%–
20% to total proximal TRP (Segawa et al. 2002; Ohkido
et al. 2003). However, the phenotype of Npt2a-null mice
improves with age (Beck et al. 1998), suggesting that
Npt2c or other renal sodium-dependent phosphate co-
transporters can rescue these mice from more-severe hy-
pophosphatemia and thus more-prominent and lifelong
bone changes.
Npt2c expression in the kidneys of Npt2a-null mice
is three- to fourfold higher than that of wild-type litter-
mates (Tenenhouse et al. 2003). Furthermore, normal
animals exhibit a more robust increase in Npt2c than
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Table 5
SLC34A3 Variations
Region and Change in
Nucleotide (Amino Acid) Region Primers
Coding region:
c.73C/T (p.L25) Exon 2 17 and 18
c.399G/A (p.Q133) Exon 5 32 and 33
c.558G/A (p.Q186) Exon 6 57 and 87
c.756G/A (p.Q252) Exon 7 20 and 34
c.757T/C (p.L253) Exon 8 20 and 34
c.1538TrA (p.V513E) Exon 13 52 and 53
Noncoding region:
g.804G/A 5′ UTR 17 and 18
g.2704A/T Intron 10 21 and 22
g.3701G/C Intron 12 23 and 24
g.3736C/T Intron 12 23 and 24
NOTE.—SLC34A3 was ampliﬁed in four overlapping fragments by
PCR (for primers, see table A1) by use of DNA from VI-75, an affected
individual from the previously published Bedouin kindred (Tieder et
al. 1985, 1987) or DNA from three additional kindreds (A, C, and
D) (Jones et al. 2001). The PCR products were then subjected to
nucleotide sequence analysis; the listed polymorphisms were found in
at least two independent sequencing reactions and were conﬁrmed by
restriction endonuclease digestion. Note that c.756G/A (p.Q252) (het-
erozygous for adenine in individuals IV-4 and V-1 of kindred A) affects
a splice donor site and thus may lead to abnormal splicing.
in Npt2a in response to phosphate deprivation (Ohkido
et al. 2003; Madjdpour et al. 2004). Thus, it is con-
ceivable that Npt2c can compensate, at least partially,
for the lack of Npt2a (Tenenhouse et al. 2003). Npt2c
expression is also hormonally regulated. For example,
it is reduced by recombinant FGF23 in wild-type mice
and in Hyp mice, which display elevated levels of en-
dogenous FGF23 (Tenenhouse et al. 2003, Liu et al.
2005), and there is preliminary evidence to suggest that
Npt2c is downregulated after injection of synthetic PTH
in wild-type mice (Miyamoto et al. 2004). NaPi-IIc thus
appears to be critically involved in regulating phosphate
homeostasis. Our ﬁnding that mutations in SLC34A3
cause HHRH now provides further evidence for this
conclusion and shows that NaPi-IIc, despite its low ex-
pression levels in the kidney, plays a critical and non-
redundant role in renal phosphate conservation in
humans. Signiﬁcant but previously unappreciated dif-
ferences in the temporospacial regulation of its expres-
sion and/or direct or indirect interaction or functional
interdependence with other cotransporters and regula-
tory and/or scaffolding proteins could explain why the
importance of NaPi-IIc in normal phosphate homeostasis
has remained undetected so far.
Npt2a haploinsufﬁciency leads to a blunted adaptive
response to a low-phosphate diet in mice (Tenenhouse
2005), and dominant-negative NaPi-IIa mutations have
been implicated in osteoporosis and nephrolithiasis in
humans (Prie´ et al. 2002). Hypercalciuria, furthermore,
leads to the development of nephrocalcinosis in homo-
zygous Npt2a-ablated mice (Chau et al. 2003; Tenen-
house et al. 2004; Tenenhouse 2005), and both hyper-
calciuria and nephrocalcinosis can be prevented by
concomitant ablation of the 25-hydroxyvitamin D3 1a-
hydroxylase gene (Cyp27b1) or by supplementing Npt2a-
deﬁcient animals with oral phosphate (Tenenhouse et al.
2004). Despite similar biochemical changes seen in het-
erozygous and homozygous carriers of SLC34A3 mu-
tations, it is surprising that hypercalciuria does not lead
to nephrolithiasis or nephrocalcinosis in most patients
with HHRH, unless the affected individuals are inap-
propriately treated with vitamin D analogs (Chen et al.
1989; Tieder et al. 1993). The index patient of kindred
A, however, presented with nephrocalcinosis, which re-
solved after treatment with phosphate supplements, and
the index patient of kindred C passed a calcium oxalate
stone 1 year before the diagnosis of HHRH was estab-
lished. Thus, the involvement of NaPi-IIc in the patho-
genesis of nephrolithiasis and nephrocalcinosis remains
to be clariﬁed. Furthermore, analysis of samples from
the general population is needed to determine whether
common variants of SLC34A3 can affect urinary cal-
cium excretion.
Mice homozygous for the ablation of Npt2a do not
develop rickets (Beck et al. 1998). In fact, these animals
have an increased BMD compared with that of wild-
type littermates (Tenenhouse 2005), which is thought
to be related to increased trabecular thickness and de-
creased number and activity of osteoclasts, which ex-
press Npt2a (Gupta et al. 2001). This is in contrast to
patients with HHRH, who usually develop bone changes
consistent with rickets. Thus, NaPi-IIc may affect—
either directly or indirectly via hypophosphatemia and
elevated 1,25(OH)2D levels—skeletal function in a man-
ner that is fundamentally different from that of NaPi-
IIa. The basis for these differences, however, is not un-
derstood at this time.
Presumed Mechanism of the Identiﬁed SLC34A3
Mutations
Although the homozygous deletion of nucleotide 228
is predicted to result in a truncated and presumably non-
functional protein (see ﬁg. 3), the mechanism(s) through
which the identiﬁed compound heterozygous mutations
lead to a complete or partial loss of function is less
apparent. However, the ﬁve identiﬁed missense and in-
frame deletion mutations were not found in healthy con-
trols, and all involve conserved amino acid residues that
are located either in intracellular loops (ICLs) 1 or 3 or
their adjacent membrane-spanning domains or within
the eighth membrane-spanning domain (see ﬁg. 3). If
structure-function studies performed for NaPi-IIa can
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Figure 3 Location and type of SLC34A3 mutations identiﬁed in four kindreds with HHRH. Upper panel, Predicted NaPi-IIc, with eight
membrane-spanning domains. The approximate locations of point mutations are shown in black letters on a white background if they affect
identical amino acid residues in the NaPi-IIc molecules of human, mouse, rat, and dog; they are depicted in white letters on a black background
if they affect amino acid residues that are identical in all type II sodium-phosphate cotransporters. The c.228delC deletion (black arrow) is
predicted to lead to truncation of NaPi-IIc within the ﬁrst membrane-spanning domain. Lower panel, Partial sequence of human NaPi types
IIa, IIb, and IIc. Species alignments were performed using Clustal W1.8 (Higgins et al. 1996). Amino acid residues are shown in white letters
on black if they are identical in several sodium-phosphate cotransporter types (type IIa: human, rat, mouse, dog, chimpanzee, and chicken; type
IIb: human, rat, mouse, dog, chimpanzee, and chicken; type IIc: human, rat, mouse, and dog). Amino acid residues are shown in black letters
on gray if they are identical in all listed species for one sodium-phosphate cotransporter type. Amino acid residues not conserved among species
for one sodium-phosphate cotransporter type are shown in black letters on white. Gray horizontal bars indicate the predicted location of
membrane-spanning domains in NaPi-IIc (see Segawa et al. 2002). Squares above the IIa sequence indicate amino acid residues identiﬁed by
site-directed mutagenesis in mouse and rat NaPi-IIa that are important for transport function, circles indicate residues important for PTH-
mediated internalization, and asterisks (*) indicate cysteine residues thought to form intramolecular cysteine bonds. Black arrowheads indicate
residues affected by point mutations. Two of these residues, S192 and G196, when mutated in the corresponding position of mouse Npt2c to
the respective residues of mouse Npt2a, confer 3:1 sodium:phosphate stoichiometry and electrogenicity to Npt2c (Bacconi et al. 2005). See
Web Resources for GenBank accession numbers of sequences.
predict functionally important domains or residues in
the closely related NaPi-IIc, the identiﬁed SLC34A3
mutations are likely to have signiﬁcant functional
consequences.
The capacity of the proximal tubule to reabsorb phos-
phate is determined by the amount of NaPi-II cotrans-
porters residing in the brush border membrane. Site-
directed mutagenesis and functional analysis of NaPi-IIa
through the substituted cysteine accessibility method
identiﬁed a dibasic motif K/R-K in the third ICL, which
appears to be important for NaPi-IIa internalization in-
duced by PTH (Karim-Jimenez et al. 2000). By use of
the same experimental approach, several residues iden-
tiﬁed in the ﬁrst extracellular loop (ECL), ﬁrst ICL, and
third ECL appear to be important for transport function,
and the PRE motif in the third ECL determines pH-
dependence of NaPi-IIa (Forster et al. 2002). Further-
more, the terminal three amino acid residues TRL and
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the PR motif in the C-terminal intracellular tail confer
binding to PDZ-domain–containing proteins such as
NHERF-1, thus permitting apical membrane insertion
of this cotransporter (Karim-Jimenez et al. 2001). On
the basis of these studies, it is possible that the missense
mutations located within the ﬁrst ICL or adjacent trans-
membrane domains affect transporter function, whereas
mutations within the third ICL could potentially affect
hormonal regulation of NaPi-IIc expression (Hernando
et al. 2005; Virkki et al. 2005). Interestingly, 2 aa in
NaPi-IIc (S192 and G196) that are mutated in some of
our patients with HHRH were recently shown to be
important determinants of stoichiometry and electro-
neutrality in the mouse ortholog Npt2c (Bacconi et al.
2005). When one of these residues was changed to al-
anine, or the other to asparagine (i.e., the residues found
at these positions in Npt2a), mouse Npt2c became elec-
trogenic, with a 3:1 sodium:phosphate stoichiometry,
which is identical to that of mouse Npt2a. Mutations
in these residues may thus lead to loss of function of
NaPi-IIc in our patients with HHRH.
The intronic 101-bp deletion g.2259_2359del, iden-
tiﬁed on one allele in a single patient with HHRH (kin-
dred C), may affect transcription or splicing of pre-
mRNA between exons 9 and 10. Since this change in
nucleotide sequence was not found in control samples,
it also could provide a plausible explanation, if associ-
ated with a mutation on the second allele, for the de-
velopment of HHRH.
It is likely that the laboratory abnormalities associated
with some of the identiﬁed point mutations are the result
of haploinsufﬁciency. However, a dominant-negative
impact on wild-type NaPi-IIc derived from the intact
SLC34A3 allele, or possibly on other sodium-phosphate
cotransporters, such as NaPi-IIa, could also be consid-
ered. Functional in vitro studies are therefore needed to
explore the impact of some of the mutations reported
here.
Expressivity of SLC34A3 Mutations
On the basis of the ﬁndings in kindred D, it is con-
ceivable that the identiﬁed SLC34A3 mutations do not
lead to full expression of the clinical phenotype. In fact,
in this kindred, not all individuals with compound het-
erozygous NaPi-IIc mutations developed HHRH; in-
stead, some showed a milder phenotype (table 3). Fur-
thermore, we found a homozygous c.228delC mutation
in ﬁve individuals of the Bedouin kindred who were
initially classiﬁed as having idiopathic hypercalciuria
(data not shown), although subtle bone changes may
have been missed. Consistent with these genetic ﬁndings,
Tieder et al. (1985, 1987) demonstrated, in the Bedouin
kindred, a signiﬁcant overlap of the tubular maximum
for phosphate reabsorption per glomerular ﬁltration
rate (TmP/GFR) and serum phosphate levels between
healthy controls and individuals with hypercalciuria and
between hypercalciuric individuals and patients with
HHRH.
Similarly, heterozygous SLC34A3mutations may lead
to additional biochemical abnormalities besides hyper-
calciuria. For example, several members of the Bedouin
kindred, who were shown here to be heterozygous for
the c.228delC mutation, displayed mild hypophospha-
temia, reduced TmP/GFR, and elevations in 1,25(OH)2D
levels in addition to increased urinary calcium excretion
(Tieder et al. 1985, 1987). Furthermore, heterozygosity
for one of the missense mutations in the other kindreds
was associated with increased calcium excretion and
other laboratory abnormalities, such as hypophospha-
temia and elevated serum 1,25(OH)2D levels; these mu-
tations included c.586GrA (p.G196R) (IV-4 in kindred
A), c.1402CrT (p.R468W) (V-3 and his mother IV-3 in
kindred A), and c.1579_1581del (p.L527del) (II-1 and
II-2, and possibly I-2 and I-3, in kindred D).
However, loss of one SLC34A3 allele does not always
lead to laboratory abnormalities. For example, in the
Bedouin kindred, heterozygosity for the c.228delC mu-
tation did not lead to hypercalciuria in individuals V-
10 and V-75, which indicates that additional factors
contribute to the presence or absence of these urinary
changes. Further investigations are thus required to iden-
tify environmental and/or genetic factors that affect ex-
pressivity of SLC34A3 mutations.
In summary, homozygous or compound heterozygous
mutations in SLC34A3 were identiﬁed as the most plau-
sible cause of HHRH in affected individuals from several
different kindreds. Our data indicate that NaPi-IIc has
a more prominent role in renal phosphate handling than
previously thought.
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Appendix A
Table A1
Primers for PCR Ampliﬁcation and Nucleotide Sequence Analysis
Primer
Primer Sequence
(5′r3′) Orientation
17 TGGAGGTCCTAGCCACAGAG Forward
18 GTCCCATTTCCTCCTCTTCC Reverse
19 CCTCCAGTTCTGCTCCAGTC Forward
20 CGCACCAGTGCTTAATGAGA Reverse
21 CCTGCTGGAGAGGCTAAGTG Forward
22 AGGAGGTCTCAAGGGAGGAGA Reverse
23 CACAGGTCCTGCACACATTTC Forward
24 CCATTCCTTGGGAGCTTC Reverse
25 TGACAGGATGGAGACAAG Forward
26 AGGAGCCTTGAAGTGGTG Forward
27 CGTCTCGGCTTGATAAGG Reverse
28 TCTCTGACACGCGCGTCC Forward
29 TGGTCAGACTGGTGAAGG Reverse
30 TTGGAGGAAGGGGACACA Forward
31 GGCCTGCCAGCCTGCCAC Reverse
32 GAGGGCCAGCCAGGGACA Forward
33 AGTCAGCCTGCGGCCCAC Reverse
34 CGTGGGTGCACACTCCCT Forward
35 TGCTGTTAGTGGCGTTGC Reverse
36 AGCTAGCCCTGGGTGCCG Forward
37 TCACACCCTCCCTGCGTC Forward
38 GACGCAGGGAGGGTGTGA Reverse
39 CCGAAACTCCGGGTCATG Forward
43 TCCCCAGCGGCTGCCGTG Reverse
44 GCATGGAGCTGGCCGCTG Forward
45 CTCTGACCTCTGTCTGCC Forward
46 CAGGGCTGACCCAGCATC Forward
47 GGAAGGGGAAGTCTATGG Reverse
52 CATCCACTTCTTCTTCAACCTG Forward
53 TCCAGAGAATGGAGCCAGAC Reverse
58 AATGTGTGCAGGACCTGT Reverse
102 CCTCCCCGGGTGGTGG Forward
103 CACTTAGCCTCTCCAGCAGG Reverse
173 CGTGCACAGAGAAGAACAGC Forward
174 GGAAGTCTATGGGGGATGCT Reverse
NOTE.—For PCR, thermal cycler conditions (Mastercycler gradi-
ent) after an initial denaturation at 94C for 5 min were 35 cycles
at 94C for 1 min, 60C or 65C for 1 min, and 72C for 3 min,
followed by a ﬁnal extension at 72C for 10 min.
Table A2
Multiplex PCR Assays
POLYMORPHISM
NUCLEOTIDE SEQUENCE
(5′r3′)
Forward Primer Reverse Primer Probe
c.586GrA ACGTTGGATGCAGCACTGTGAGCCAGTTGA ACGTTGGATGTGACCCTGCCCACTCTCTG GAGCCAGTTGAAGATCC
c.575CrT ACGTTGGATGTGTGAGCCAGTTGAAGATCC ACGTTGGATGTGACCCTGCCCACTCTCTG AGATCCCGTGCACCGCC
NOTE.—Please note that the PCR primers all have a 5′ tail of 10 bases (ACGTTGGATG), which can be used for nucleotide sequence analysis.
PCR reactions were performed in a 384-well format. In brief, 2.5 ng of genomic DNA was ampliﬁed in a 5-ml reaction containing 1# HotStar Taq
PCR buffer (Qiagen), 2.5 mM MgCl2, 200 mM of each dNTP, 50 nM of each PCR primer, and 0.1 U HotStar Taq (Qiagen). The reaction was
incubated at 95C for 15 min, followed by 45 cycles at 95C for 20 s, 56C for 30 s, and 72C for 1 min, with a ﬁnal step at 72C for 3 min.
Excess dNTPs were then removed from the reaction by incubation with 0.3 U shrimp alkaline phosphatase (USB) at 37C for 20 min, followed by
5 min at 85C to deactivate the enzyme. Single-primer extension over the SNP or insertion/deletion was performed in a ﬁnal concentration of 600
nM of each extension primer (probe), 50 mM d/ddNTP, and 0.126 U Thermosequenase (USB) and was incubated at 94C for 2 min, followed by
45 cycles at 94C for 5 s, 52C for 5 s, and 72C for 5 s. The reaction was then desalted by addition of a cation exchange resin followed by mixing
and centrifugation to precipitate the contents of the tube. The extension product was then spotted onto a 384-well spectroCHIP before being ﬂown
in the MALDI-TOF mass spectrometer.
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Web Resources
Accession numbers and URLs for data presented herein are as
follows:
dbSNP, http://www.ncbi.nlm.nih.gov/SNP/
GenBank, http://www.ncbi.nlm.nih.gov/Genbank/ (for SLC34A3 ge-
nomic contig [909158 in accession numberNT_024000.16, or phys-
ical map nucleotide chr9:137401992 in human genome release
March 2004], cDNA [187 in accession number NM_080877.1], and
protein [accession number NP_543153.1]; SLC34A1 (NaPi-IIa) pro-
tein sequences for Homo sapiens [accession number NP_003043.2],
Canis familiaris [accession number XP_536418.1], Pan troglo-
dytes [accession number XP_518129.1], Rattus norvegicus [acces-
sion number NP_037162.1], Mus musculus [accession number
NP_035522.1], andGallus gallus [accession numberXP_425204.1];
SLC34A2 (NaPi-IIb) protein sequences for H. sapiens [acces-
sion number NP_006415.1], C. familiaris [accession number
XP_545968.1], P. troglodytes [accession number XP_526805.1],R.
norvegicus [accession number XP_579555.1], M. musculus [acces-
sion number NP_035532.2], and G. gallus [accession number
NP_989805.1]; and SLC34A3 (NaPi-IIc) protein sequences for C.
familiaris [accession number XP_548353.1], R. norvegicus [acces-
sion number NP_647554.1], and M. musculus [accession number
NP_543130.1])
Marshﬁeld Center for Medical Genetics, http://www2.marshﬁeldclinic
.org/research/genetics/ (for Marshﬁeld genetic maps)
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm
.nih.gov/Omim/ (for HHRH, XLH, and ADHR)
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